TAK

Takeda Pharmaceutical Co Ltd: FY2025 Earnings Summary

Business Context and Reporting Period

This Form 6-K filing reports the consolidated financial results for Takeda Pharmaceutical Company Limited for the fiscal year ended March 31, 2025. The report was filed on May 8, 2025. Takeda is a global biopharmaceutical company with operations in approximately 80 countries, focusing on six key business areas: Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT), Oncology, Vaccines, and Neuroscience.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Driven by favorable foreign exchange rates and growth in GI (ENTYVIO), Rare Diseases (TAKHZYRO), PDT, Oncology (FRUZAQLA), and Vaccines (QDENGA). This was partially offset by a decline in Neuroscience due to generic erosion of VYVANSE sales in the U.S.
• Operating Profit Surge: Operating profit increased significantly (+60.0%) primarily due to lower impairment charges compared to the prior year (which included significant charges for ALOFISEL and EXKIVITY) and reduced restructuring costs.
• Net Profit Decline: Despite higher operating profit, net profit fell by 25.1% due to a reversal of a tax benefit recorded in FY2024 (related to an Irish tax assessment) and higher current tax expenses.
• Balance Sheet: Total assets decreased by JPY 860.4 billion, mainly due to amortization and impairment of intangible assets and the sale of Teva Takeda Pharma Ltd. shares. Total liabilities decreased by JPY 522.4 billion following debt repayments.
• Dividends: The annual dividend was increased to JPY 196 per share (up from JPY 188 in FY2024).

Guidance, Outlook, and Risks

FY2026 Forecast (Ending March 31, 2026):

• Revenue: Forecast at JPY 4,530.0 billion (-1.1% vs. FY2025), expected to be broadly flat due to offsetting growth from new products and declines from loss of exclusivity (VYVANSE).
• Operating Profit: Forecast at JPY 475.0 billion (+38.7%), driven by lower restructuring expenses, the conclusion of VYVANSE amortization, and lower impairment assumptions.
• Net Profit: Forecast at JPY 228.0 billion (+111.3%), reflecting the increase in operating profit and a lower effective tax rate assumption (~26%).
• Management Guidance (CER): Core Revenue, Core Operating Profit, and Core EPS are all projected to be "Broadly Flat" on a Constant Exchange Rate basis.

Risks and Contingencies:

• Product Liability: Takeda reached a settlement agreement in principle regarding U.S. product liability lawsuits related to PREVACID and DEXILANT (PPI claims). The settlement amount is non-material.
• Tariffs: Potential U.S. and China tariffs could impact the business, though Takeda currently estimates limited exposure based on import values and manufacturing locations.
• Generic Competition: Continued erosion of VYVANSE sales in the U.S. and AZILVA in Japan due to generic entry.

Investor Verification Checklist

• Core vs. GAAP Divergence: Verify the significant difference between GAAP Net Profit (down 25%) and Core Net Profit (up 2.5%) to understand the impact of one-time tax items and impairments.
• VYVANSE Trajectory: Monitor the continued decline in Neuroscience revenue as generic competition intensifies, which is a key headwind in the FY2026 forecast.
• Debt Management: Review the reduction in total bonds and loans (down JPY 328.5 billion) and the issuance of new long-term hybrid bonds and senior notes to assess liquidity and interest rate exposure.
• Impairment Assumptions: Scrutinize the FY2026 forecast assumption of JPY 50.0 billion in impairment losses, which is significantly lower than the JPY 95.0 billion recorded in FY2025.
• FX Sensitivity: Note that FY2025 results benefited from a weaker yen; the FY2026 forecast assumes a stronger yen (150 JPY/USD vs. 152 JPY/USD in FY2025), which may pressure reported revenue.